Skip to content

Texas House Bill 3703: What You Need to Know

Texas House Bill 3703: What You Need to Know

The state of Texas has been in the news in recent months as the legislature review House Bill 3703. This bill relates to “the prescription of low-THC cannabis for medical use by certain qualified physicians to patients with [specific] qualifying conditions”. Originally filed in March of 2019, this bill made its way through the house for the next three months and was finally signed off by the governor and passed into law on June 14, 2019.

HB 3703 was authored by Republican state Rep. Stephanie Klick of Fort Worth, who had also written the state’s Compassionate Use Act back in 2015. While Klick did not sign onto a bill in 2017 that would’ve drastically expanded her 2015 measure, she recently reported that she believes “opinions on this medicine have changed,” which is the reason why she had written this year’s bill for expansion of the medical marijuana program.

What Does this Bill Do?

The feature of HB 3703 that is most notable is the expansion in the list of qualifying conditions physicians can prescribe. Before this bill, the only qualifying condition that could be treated legally with medical marijuana is the condition of intractable epilepsy-and only if two physicians concur that other treatments have been ineffective and medical cannabis is a necessary treatment.

Now, HB 3703 removes the need for two physicians and expands the qualifying conditions list to include:

  • Epilepsy (no longer specifically “intractable” epilepsy)
  • Seizure disorders
  • Multiple sclerosis
  • Spasticity
  • Amyotrophic lateral sclerosis (ALS)
  • Autism
  • Terminal cancer
  • Incurable neurodegenerative diseases (i.e. Alzheimer’s, Parkinson’s, Huntington’s)

While this measure eliminates the two-physician requirement, any prescribing physician must be “board certified in a medical specialty relevant to the treatment of the patient’s particular medical condition by a specialty board approved by the American Board of Medical Specialties or the Bureau of Osteopathic Specialists”.

What Does this Bill NOT Do?

Despite the extraordinary advances in the legalization of medical cannabis for Texas, this bill does fall short in a few areas. HB 3703 does not negate the state’s current 0.5% THC limit on cannabis products. The problem with this is the fact that 0.5% is significantly lower than what’s available in other states. These states allow for cured cannabis to contain 30% THC levels with some concentrations containing more.

In addition to not increasing the legal amount of THC in cannabis products, this bill also leaves out some qualifying conditions that supporters fought hard to incorporate. Among these excluded qualifying conditions are chronic pain and post-traumatic stress disorder (PTSD), two of the more common qualifying conditions for medical marijuana. Advocates will have to wait until the 2021 legislative session to readdress the addition of these left out qualifying conditions.

While this is one great step forward for medical cannabis in Texas, there is still quite a bit of work to be done. One of the main comments and arguments during the debate period was the problem of not enough data. “We just don’t have the data—good scientific data—that supports PTSD that we can put in the bill at this time,” Campbell said, according to The Texas Tribune. Enter: Arfinn Med.

At Arfinn Med, we believe that the most successful treatment outcomes involve collaboration between medical professionals and patients. With our platform, physicians can record, track and report on medical marijuana treatment plans and efficacies. By joining Arfinn Med, physicians will have access to real, credible data collected from their own practice and case files submitted by licensed physicians throughout the U.S. Ready to learn more? Register today and join a nation-wide network of licensed physicians prescribing medical cannabis.

Sources:

https://legiscan.com/TX/bill/HB3703/2019

https://www.leafly.com/news/politics/texas-lawmakers-expand-medical-cannabis-qualifying-conditions

https://www.texastribune.org/2019/05/22/texas-cannabis-oil-access-expanded-senate/

https://www.texastribune.org/2019/03/07/texas-stephanie-klick-marijuana-compassionate-use-act/

Stories you may be interested in

Substance in cannabis ‘could boost pancreatic cancer treatments’

A substance found in cannabis plants might boost treatments for patients with pancreatic cancer, research in mice has suggested. Cannabidiol, or CBD, is not psychoactive, meaning it does not produce feelings of being high in those who take it. It is extracted from hemp plants and is legal in the UK, although a CBD product…
Read More

Three Key Voices in the Medical Marijuana Industry

As medical marijuana programs continue to expand throughout the United States, it is important to recognize some of the key voices throughout the industry that got us here. These individuals range from researches to physicians and even to patients who started their own advocacy group. Keep reading to learn about just three of the many…
Read More

Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders

Report of the Guideline Development Subcommittee of the American Academy of Neurology:   We performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. Read the full…
Read More

After A Decade Of Testing, Israeli Medical Cannabis Comes To The US

Cannabis is still federally illegal, so while more than 30 US states allow doctors to recommend it, there is very little medical testing of the substance in America. In Israel however, medical cannabis has been legal for more than ten years and studies on the plant’s ability to alleviate the side-effects of cancer and ease…
Read More

Norfolk research company plans clinical trials using medical marijuana

Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions. Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer.…
Read More

Cannabis improves symptoms of Crohn’s disease despite having no effect on gut inflammation

In the first study of its kind, cannabis oil has been shown to significantly improve the symptoms of Crohn’s disease and the quality of life of sufferers but, contrary to previous medical thinking, has no effect on gut inflammation. In a randomised, placebo-controlled study, researchers from Israel have shown that cannabis can produce clinical remission…
Read More

Leave a Comment

You must be logged in to post a comment.